Value
8.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 9.7 |
| Analyst target | 7.5 |
- ▸Attractively valued
TOI · Why this verdict
Why The Oncology Institute (TOI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock trips 3 of 5 value-trap signals, including margin compression with an operating margin of -39.8% and negative free cash flow. Warnings | Operating margin should improve, rising above -20%, over the next 12 months to move away from value-trap territory. | →Stable |
| CounterValue-trap flags are heuristic warnings, not certainties, and a company investing heavily in growth can still re-rate positively once losses narrow. | ||
Revenue grew 41% year-over-year, marking the company as an industry growth leader within its peer group. Growth breakdown | Revenue growth should stay above 25% YoY over the next 12 months to sustain the growth-leader positioning. | →Stable |
| CounterRapid top-line growth at a cash-burning healthcare services company can mask unsustainable unit economics if margins don't follow. | ||
The company is cash-burning with free cash flow at -3% of revenue and a weak Piotroski F-Score of 2 out of 9, reflecting below-average business quality. Quality breakdown | Free cash flow should turn positive, exceeding 0% of revenue, over the next 12 months if profitability genuinely improves. | →Stable |
| CounterCash burn during a scaling phase is common for growth healthcare providers and doesn't necessarily preclude an eventual profitable inflection. | ||
The company beat EPS estimates in its two most recent quarters, with an average earnings surprise of 15.5% across the last four quarters. Earnings | The beat streak should extend to at least 3 of the next 4 quarters if execution momentum continues. | →Stable |
| CounterA beat streak against depressed loss estimates is a low bar and may not reflect genuine operating improvement. | ||
The stock trips 3 of 5 value-trap signals, including margin compression with an operating margin of -39.8% and negative free cash flow.
→StableWarnings
- Expectation
- Operating margin should improve, rising above -20%, over the next 12 months to move away from value-trap territory.
CounterValue-trap flags are heuristic warnings, not certainties, and a company investing heavily in growth can still re-rate positively once losses narrow.
Revenue grew 41% year-over-year, marking the company as an industry growth leader within its peer group.
→StableGrowth breakdown
- Expectation
- Revenue growth should stay above 25% YoY over the next 12 months to sustain the growth-leader positioning.
CounterRapid top-line growth at a cash-burning healthcare services company can mask unsustainable unit economics if margins don't follow.
The company is cash-burning with free cash flow at -3% of revenue and a weak Piotroski F-Score of 2 out of 9, reflecting below-average business quality.
→StableQuality breakdown
- Expectation
- Free cash flow should turn positive, exceeding 0% of revenue, over the next 12 months if profitability genuinely improves.
CounterCash burn during a scaling phase is common for growth healthcare providers and doesn't necessarily preclude an eventual profitable inflection.
The company beat EPS estimates in its two most recent quarters, with an average earnings surprise of 15.5% across the last four quarters.
→StableEarnings
- Expectation
- The beat streak should extend to at least 3 of the next 4 quarters if execution momentum continues.
CounterA beat streak against depressed loss estimates is a low bar and may not reflect genuine operating improvement.
TrendMatrix Research · core thesis
Engine thesis — one sentence
The Oncology Institute shows strong revenue growth and a recent earnings-beat streak, but weak business quality, cash-burning free cash flow, and value-trap warning signals raise doubts about the durability of the growth story.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.4 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -3% of revenue
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 41% YoY
Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 6.6 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 4.3 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 5.0 |
| Price target | 9.0 |
- ▸Analyst upside: 37%
Insider
7.8/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 10.0 |
- ▸Insider buying (low materiality) — $27,428 (0.005% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.4 |
| quality rank | 0.9 |
| growth rank | 8.9 |
- ▸Industry growth leader
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.4 |
| support resistance | 2.2 |
| 52w position | 9.0 |
| gap | 6.0 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.2 |
| days to cover | 7.1 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 10.0 |
- ▸High IV: 97%
- ▸Above max pain $1
- ▸Concentration risks: 4 MED (10-K Item 1A)
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.1<1.5@spot
Warning (0)
none
Reward-to-Risk
1.11
Upside
+16.6%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 61, MACD bullish
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilityAggressive — MCap $0.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.1<1.5@spot.
The strongest dimensions are Growth at 10.0, Value at 8.4, and Insider at 7.8; the weakest are Quality at 1.6, Technical at 4.7, and Peer rank at 5.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Topline Growth
Trip ifRevenue growth falls below 15% YoY for 2 consecutive quarters, down from the current 41%.
- P2Cash Burning Quality Concerns
Trip ifFree cash flow stays below -10% of revenue for 2 consecutive quarters, worsening from the current -3%.
- P3Value Trap Warning Signals
Trip ifOperating margin falls below -50%, deepening from the current -39.8% and confirming the margin-compression value-trap signal.
- P4Earnings Beat Momentum
Trip ifAverage earnings surprise falls below 0% for 2 consecutive quarters, reversing the current 15.5% average beat.